Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
3D Medicines, Inc. ( (HK:1244) ) just unveiled an announcement.
3D Medicines Inc. has scheduled a board meeting for March 31, 2026 to review and approve the audited annual results for the year ended December 31, 2025. The board will also consider the potential declaration of a final dividend, a decision that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also confirms the current composition of the company’s board, comprising an executive director, several non-executive directors and independent non-executive directors. This governance structure underscores regulatory compliance and oversight as the company prepares to release its full-year financial results to the market.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange. The company operates in the biopharmaceutical sector, focusing on the development and commercialization of innovative medicines, with its shares traded under stock code 1244.
Average Trading Volume: 127,939
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.06B
See more data about 1244 stock on TipRanks’ Stock Analysis page.